Cargando…

Erratum: Mcl-1 Inhibition: Managing Malignancy in Multiple Myeloma

Detalles Bibliográficos
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2021
Materias:	Pharmacology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8438299/ https://www.ncbi.nlm.nih.gov/pubmed/34531757 http://dx.doi.org/10.3389/fphar.2021.758130

Ejemplares similares

Mcl-1 Inhibition: Managing Malignancy in Multiple Myeloma
por: Al-Odat, Omar S., et al.
Publicado: (2021)

3-Chloroplumbagin Induces Cell Death in Breast Cancer Cells Through MAPK-Mediated Mcl-1 Inhibition
por: Kawiak, Anna, et al.
Publicado: (2019)

Targeting B-cell maturation antigen increases sensitivity of multiple myeloma cells to MCL-1 inhibition
por: Cuenca, Marta, et al.
Publicado: (2021)

Development of an MCL-1-related prognostic signature and inhibitors screening for glioblastoma
por: Zhang, Ao, et al.
Publicado: (2023)

Multiple myeloma induces Mcl-1 expression and survival of myeloid-derived suppressor cells
por: De Veirman, Kim, et al.
Publicado: (2015)

Silence of MCL-1 upstream signaling by shRNA abrogates multiple myeloma growth
por: Wang, Mengchang, et al.
Publicado: (2014)

Gossypol induces apoptosis in multiple myeloma cells by inhibition of interleukin-6 signaling and Bcl-2/Mcl-1 pathway
por: SADAHIRA, KEN, et al.
Publicado: (2014)

Comprehensive elaboration of circular RNA in multiple myeloma
por: Zhu, Chunsheng, et al.
Publicado: (2022)

Circumvention of Mcl-1-Dependent Drug Resistance by Simultaneous Chk1 and MEK1/2 Inhibition in Human Multiple Myeloma Cells
por: Pei, Xin-Yan, et al.
Publicado: (2014)

SHP2 Inhibitors Show Anti-Myeloma Activity and Synergize With Bortezomib in the Treatment of Multiple Myeloma
por: Zhou, Pan, et al.
Publicado: (2022)

Multiple myeloma: challenges with deciding the optimal sequencing strategy
por: Walia, Anushka, et al.
Publicado: (2023)

Phosphatase PP2A enhances MCL-1 protein half-life in multiple myeloma cells
por: Slomp, Anne, et al.
Publicado: (2021)

Synergistic interaction between HDAC and MCL-1 inhibitors through downregulation of BCL-XL in multiple myeloma
por: Schneller, Anja, et al.
Publicado: (2021)

Preclinical efficacy of sepantronium bromide (YM155) in multiple myeloma is conferred by down regulation of Mcl-1
por: Wagner, Verena, et al.
Publicado: (2014)

Analysis of the Metabolic Characteristics of Serum Samples in Patients With Multiple Myeloma
por: Du, Haiwei, et al.
Publicado: (2018)

1,2,3,4,6-Penta-O-Galloyl-Beta-D-Glucopyranoside Inhibits Proliferation of Multiple Myeloma Cells Accompanied with Suppression of MYC Expression
por: Tseeleesuren, Duurenjargal, et al.
Publicado: (2018)

Validation of an Instrument for Measuring Adherence to Treatment With Immunomodulators in Patients With Multiple Myeloma
por: Silveira, Lívia Pena, et al.
Publicado: (2021)

Shengma Biejia Decoction Inhibits Cell Growth in Multiple Myeloma by Inducing Autophagy-Mediated Apoptosis Through the ERK/mTOR Pathway
por: Dai, Huibo, et al.
Publicado: (2021)

Discovery of Mcl-1-specific inhibitor AZD5991 and preclinical activity in multiple myeloma and acute myeloid leukemia
por: Tron, Adriana E., et al.
Publicado: (2018)

MCL-1 inhibition in cancer treatment
por: Xiang, Weiguo, et al.
Publicado: (2018)

Hotspots and trends in multiple myeloma bone diseases: A bibliometric visualization analysis
por: Hou, Zhaomeng, et al.
Publicado: (2022)

Comprehensive analysis of ferroptosis-related genes in immune infiltration and prognosis in multiple myeloma
por: Wang, Quanqiang, et al.
Publicado: (2023)

Engineered Exosomes-Mediated Transfer of hsa-miR-320a Overcomes Chemoresistance in Cervical Cancer Cells via Targeting MCL1
por: Zhou, Jinling, et al.
Publicado: (2022)

Baohuoside I Inhibits Tumor Angiogenesis in Multiple Myeloma via the Peroxisome Proliferator–Activated Receptor γ/Vascular Endothelial Growth Factor Signaling Pathway
por: Chen, Ying, et al.
Publicado: (2022)

Cost-Effectiveness Analysis of Adding Daratumumab to Bortezomib, Melphalan, and Prednisone for Untreated Multiple Myeloma
por: Cao, Yaohua, et al.
Publicado: (2021)

Mechanisms of action of the BCL-2 inhibitor venetoclax in multiple myeloma: a literature review
por: Cao, Qiang, et al.
Publicado: (2023)

Heterogeneous modulation of Bcl-2 family members and drug efflux mediate MCL-1 inhibitor resistance in multiple myeloma
por: Bolomsky, Arnold, et al.
Publicado: (2021)

Mcl-1 Expression Is Up-Regulated in Malignancies of the Parotid Gland
por: Heiduschka, Gregor, et al.
Publicado: (2011)

Allosteric Inhibition of Anti-Apoptotic MCL-1
por: Lee, Susan, et al.
Publicado: (2016)

Resveratrol Sensitizes Carfilzomib-Induced Apoptosis via Promoting Oxidative Stress in Multiple Myeloma Cells
por: Li, Qian, et al.
Publicado: (2018)

Active Components of Traditional Chinese Medicinal Material for Multiple Myeloma: Current Evidence and Future Directions
por: Yu, Chao-Chao, et al.
Publicado: (2022)

Pomalidomide enhances the maturation of dendritic cells derived from healthy donors and multiple myeloma patients
por: Wang, Xi, et al.
Publicado: (2022)

Withanolide D Exhibits Similar Cytostatic Effect in Drug-Resistant and Drug-Sensitive Multiple Myeloma Cells
por: Issa, Mark E., et al.
Publicado: (2017)

Treatment attrition rates and relevant risk factors in multiple myeloma: A real-world study in China
por: Tang, Wenjiao, et al.
Publicado: (2023)

The multiple mechanisms of MCL1 in the regulation of cell fate
por: Widden, Hayley, et al.
Publicado: (2021)

Erratum: Advances in RIPK1 kinase inhibitors
Publicado: (2023)

YM155 exerts potent cytotoxic activity against quiescent (G(0)/G(1)) multiple myeloma and bortezomib resistant cells via inhibition of survivin and Mcl-1
por: Ookura, Miyuki, et al.
Publicado: (2017)

Long-Term Efficacy of Maintenance Therapy for Multiple Myeloma: A Quantitative Synthesis of 22 Randomized Controlled Trials
por: Li, Jie-Li, et al.
Publicado: (2018)

Celastrol Attenuates the Invasion and Migration and Augments the Anticancer Effects of Bortezomib in a Xenograft Mouse Model of Multiple Myeloma
por: Shanmugam, Muthu K., et al.
Publicado: (2018)

Upregulation of lncRNA NR_046683 Serves as a Prognostic Biomarker and Potential Drug Target for Multiple Myeloma
por: Dong, Hang, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_9p25pc20b1sb4u8ii38jm5efan